Interleukin-33¹¹ Interleukin-33
IL-33 is an alarmin cytokine constitutively expressed in the nuclei of airway epithelial and endothelial cells; when tissue is damaged by allergens, viruses, or mechanical stress, IL-33 is passively released from ruptured cells and triggers immediate type 2 immune activation sits at the very top of the type 2 inflammatory cascade that drives asthma, allergic rhinitis, and atopic sensitization. The IL33 gene on chromosome 9p24.1 is one of the most replicated asthma susceptibility loci in human genetics, and variants at this locus reliably associate with altered IL-33 expression levels in bronchial epithelium, plasma IL-33 protein concentration, and lifetime asthma risk. rs12551256 is an intronic variant within IL33 at GRCh38 chr9:6,231,239. The G allele was negatively associated with asthma in a 1,223-person Brazilian cohort (OR 0.71, P=0.017), suggesting it may sit within or near a regulatory element that modulates IL-33 expression or splicing efficiency.

The Mechanism

After tissue damage, IL-33 is released from the nucleus and binds its receptor complex ST2/IL-1RAcP on mast cells, basophils, and group 2 innate lymphoid cells²² group 2 innate lymphoid cells
ILC2s are innate immune cells that respond to epithelial alarmins (IL-33, IL-25, TSLP) without requiring antigen presentation; they are the dominant early source of IL-5 and IL-13 that drives eosinophilic airway inflammation. Binding activates MyD88→TRAF6→NF-κB and MAPK cascades, causing ILC2s and mast cells to flood the airway with IL-5 (driving eosinophilia), IL-13 (driving mucus and bronchospasm), and IL-9 (driving further mast cell activation). Environmental allergen proteases amplify this loop by cleaving full-length IL-33 into shorter, hyper-potent active forms. Variants that reduce IL-33 output from epithelial cells — whether through altered splicing efficiency, disrupted enhancer elements, or other intronic regulatory effects — blunt this entire cascade upstream of every cytokine downstream of IL-33.

The fine-mapping study at the IL33 locus³³ fine-mapping study at the IL33 locus
Aneas et al. Nature Communications 2021; identified a 5 kb enhancer-blocking element within the GWAS-defined 41 kb LD block that loops to the IL33 promoter; risk alleles rs1888909-T and rs992969-A increase bronchial epithelial IL33 mRNA and plasma IL-33 protein established that the IL33 asthma locus is an expression quantitative trait locus (eQTL) in airway epithelium, not in bulk lung tissue — meaning that the locus specifically tunes how much IL-33 is produced in the epithelial cells most exposed to inhaled triggers. rs12551256 at chr9:6,231,239 lies within the gene body of IL33, approximately 16 kb downstream of rs992969, and may mark an independent or correlated regulatory element within this same eQTL region.

The Evidence

The primary evidence for rs12551256 comes from a Brazilian case-control study⁴⁴ Brazilian case-control study
Queiroz et al., Int J Immunogenet 2017; 1,223 subjects genotyped on Illumina 2.5 Human Omni BeadChip; analyses adjusted for sex, age, helminth infection, and ancestry markers in a mixed European/African admixed population. The G allele was negatively associated with asthma (OR 0.71, 95% CI 0.53–0.94, P=0.017), a ~29% reduction in odds in heterozygotes and a larger expected reduction in GG homozygotes under an additive model. The effect size is modest and has not yet been independently replicated for this specific rsid in other cohorts — hence an evidence level of emerging.

The biological plausibility of a protective intronic variant at the IL33 locus is strongly supported by parallel human genetic evidence. The rare IL33 splice acceptor variant rs146597587-C⁵⁵ rare IL33 splice acceptor variant rs146597587-C
Zhu et al. PLoS Genet 2017; 103,104 participants for eosinophil analysis; 6,465 asthma cases vs 302,977 controls; rs146597587-C heterozygotes have ~40% lower total IL33 mRNA and a strongly protective effect on asthma risk (OR 0.47) and blood eosinophil counts (β=-0.21 SD, P=2.5×10⁻¹⁶) shows that even partial reduction in IL-33 availability provides robust protection against asthma. The clinical importance of the IL-33 pathway is confirmed by a phase 2 trial of itepekimab⁶⁶ a phase 2 trial of itepekimab
Wechsler et al. NEJM 2021; itepekimab (anti-IL-33 mAb, 300 mg SC every 2 weeks) vs placebo in moderate-to-severe asthma; loss-of-control events 22% vs 41%, OR 0.42, P=0.02, an anti-IL-33 monoclonal antibody, which achieved a 46% relative reduction in asthma loss-of-control events.

Practical Implications

Carriers of the G allele may have modestly lower IL-33 signalling capacity in their airway epithelium, which could translate to lower type 2 airway inflammation burden over a lifetime of allergen exposure. For carriers of AA (no G copies), the absence of this potential dampening variant — combined with other IL33 risk alleles at nearby positions — is a signal for proactive airway management. Practical steps include monitoring expiratory flow before symptoms develop and identifying specific aeroallergen triggers that activate airway epithelial IL-33 release (house dust mite proteases, cockroach allergens, tobacco smoke).

Interactions

rs12551256 lies within the IL33 gene body, approximately 16 kb downstream of the main asthma GWAS signal rs992969 and in the same genomic region as the cluster of IL33 eQTL variants. The degree of linkage disequilibrium between rs12551256 and nearby risk variants (rs992969, rs1888909) is not fully defined, particularly in non-European populations. In the Brazilian study population, LD patterns reflect the admixed European/African ancestry structure of the cohort.

rs146597587 (IL33 splice acceptor LOF variant) and rs992969 (IL33 upstream regulatory variant increasing IL33 expression) are the best-characterized IL33 variants in the platform. Carriers of rs12551256-GG with concurrent rs992969-GG (low-risk configuration at both loci) would represent the IL33 haplotype with the most consistent evidence for dampened IL-33-driven airway inflammation.

The receptor-side variant rs1420101 (IL1RL1/ST2) shapes how cells respond to whatever IL-33 is secreted — individuals with rs12551256-G (lower IL-33 production) and rs1420101 variants affecting sST2 decoy receptor levels have a dual dampening effect on the IL-33 → ST2 signalling axis.

Heme oxygenase 2 (HMOX2) is the constitutive enzyme responsible for breaking down free heme in the brain. Unlike its inducible sibling HMOX1, HMOX2 is always switched on — particularly in cerebral blood vessels, neurons, and astrocytes — producing three products at baseline: biliverdin¹¹ biliverdin
converted rapidly to the antioxidant bilirubin by biliverdin reductase, iron, and carbon monoxide (CO)²² carbon monoxide (CO)
a gasotransmitter: a small molecule gas with defined signalling functions in cells, analogous to nitric oxide. That constitutive CO is not merely a metabolic byproduct — it is an active vasosignalling molecule that sets the baseline tone of cerebral arterioles and interacts continuously with the nitric oxide (NO) system.

rs12598836 is an intronic variant within HMOX2 on chromosome 16p13.3. The G allele (the GRCh38 reference) is the migraine risk allele. It is carried at approximately 30% frequency in Europeans but 80% in Africans, making it one of the more population-stratified migraine risk variants identified to date.

The Mechanism

CO produced by HO-2 acts as a tonic vasoregulator³³ tonic vasoregulator
a continuous background signal that holds vascular tone within a narrow physiological range, distinct from acute vasoactive responses in cerebral microvessels. It competes directly with nitric oxide synthase (NOS): CO inhibits NOS by binding to the enzyme's heme prosthetic group, reducing NO output. When HO-2 activity is experimentally blocked, cerebral arterioles dilate — an effect reversed by adding CO back or blocking NOS. This CO-NO balance is precisely the type of vascular regulation relevant to migraine-with-aura pathophysiology.

Cortical spreading depression (CSD)⁴⁴ Cortical spreading depression (CSD)
the electrophysiological wave of neuronal depolarisation and suppression that underlies migraine aura, propagating at 3–5 mm/minute across the cortex alters cerebral blood flow in a characteristic triphasic pattern — initial hyperaemia, then oligaemia, then sustained hypoperfusion. The HMOX2/CO system, by setting baseline cerebrovascular tone and interacting with NO, is positioned mechanistically at exactly this interface between neurovascular coupling and aura. The rs12598836 G allele presumably tags a regulatory change in HMOX2 expression or splicing that shifts this CO-NO balance in a direction that lowers the threshold for CSD initiation or sustains the oligaemic phase that produces aura symptoms.

The Evidence

The primary evidence comes from Hautakangas et al. 2022⁵⁵ Hautakangas et al. 2022
Genome-wide analysis of 102,084 migraine cases identifies 123 risk loci and subtype-specific risk alleles. Nature Genetics, the largest migraine GWAS conducted to date. Among 123 genome-wide significant loci, the HMOX2 locus (rs12598836-G) was one of only three variants with subtype-specific effects exclusive to migraine with aura (14,624 MA cases vs 703,852 controls). The overall migraine odds ratio per G allele is modest — 1.038 (p = 2×10⁻¹⁰) — but the specificity for the MA subtype implicates an aura mechanism rather than the shared migraine headache pathway.

The mechanistic case rests on dedicated HO-2 neurophysiology research. Parfenova and Leffler 2008⁶⁶ Parfenova and Leffler 2008
Cerebroprotective functions of HO-2. Antioxidants & Redox Signaling documented that HO-2 maintains cerebral blood flow during seizures and hypoxia through rapid CO production — without requiring new enzyme synthesis. Ishikawa et al. 2005⁷⁷ Ishikawa et al. 2005
Microcirculation showed that HO-2-derived CO tonically antagonises NO-mediated vasodilation in rat cerebral arterioles, establishing CO from this enzyme as a moment-to-moment cerebrovascular regulator. The link to CSD is supported by Nimura et al. 1996⁸⁸ Nimura et al. 1996
Journal of Cerebral Blood Flow and Metabolism, who showed that prolonged spreading depression induces HO-1 in cortical glia via AP-1 activation — the heme oxygenase pathway responds to and is activated by CSD waves.

The evidence level for the GWAS association is moderate: the study is large and well-powered, but the HMOX2 subtype-specific finding has not yet been independently replicated in a separate MA-specific meta-analysis. The overall migraine association (p = 2×10⁻¹⁰) is genome-wide significant, but the MA-specific effect merits further confirmation.

Practical Actions

For G allele carriers, the modestly elevated migraine-with-aura susceptibility points to the importance of managing triggers that destabilise neurovascular coupling — particularly those that alter the CO-NO balance acutely. The G allele's effect size is small (OR 1.038), meaning it is one of many genetic contributors to MA risk rather than a dominant determinant. For GG homozygotes with diagnosed MA, discussing vasoconstrictor triptans (which target serotonin 5-HT1B/D receptors on cerebral vessels and are the most effective acute MA treatments) with a neurologist is appropriate given the cerebrovascular mechanism involved.

Interactions

The three MA-specific loci identified in Hautakangas 2022 — HMOX2, CACNA1A, and MPPED2 — are worth considering together. CACNA1A encodes the voltage-gated calcium channel P/Q subunit, variants in which cause familial hemiplegic migraine; calcium channel dysregulation lowers the CSD threshold independently of the vascular mechanism. HMOX2 and CACNA1A likely act through distinct pathways (neurovascular vs neuronal excitability), so co-inheritance of risk variants in both genes could have an additive effect on MA susceptibility.

rs10166942 (TRPM8) is an established migraine risk SNP in the same neurology-cognition category; TRPM8 mediates cold-triggered pain sensitivity and cerebrovascular responses, representing a distinct pathway to migraine susceptibility from the HO-2/CO axis.

LPIN1 encodes lipin-1, a dual-function protein at the heart of lipid metabolism. In the cytoplasm, lipin-1 acts as a phosphatidic acid phosphohydrolase¹¹ phosphatidic acid phosphohydrolase
A Mg²⁺-dependent enzyme that converts phosphatidic acid to diacylglycerol, the branch-point metabolite required for both triglyceride storage and phospholipid membrane synthesis. In the nucleus, lipin-1 switches roles entirely: it acts as a transcriptional co-activator of PGC-1α and PPARα, driving genes for fatty acid oxidation and mitochondrial metabolism while suppressing lipogenic gene expression. This makes LPIN1 a physiological gatekeeper that normally keeps the liver from accumulating excess fat during periods of caloric load.

The rs13412852 C>T variant sits within an intron of LPIN1 on chromosome 2 (chr2:11,774,815, GRCh38) and does not alter the protein sequence. Its functional impact is not established at the molecular level, but population studies have uncovered context-dependent associations with liver fat, triglycerides, and disease progression — associations that differ strikingly between children and adults.

The Mechanism

LPIN1 is on the plus strand of chromosome 2. The rs13412852 C allele is the GRCh38 reference allele, present on approximately 75% of chromosomes globally. The T allele (minor allele, ~25% globally) may alter intronic regulatory elements — such as splicing enhancers, microRNA binding sites in the pre-mRNA, or chromatin accessibility signals — though no specific molecular mechanism has been established.

The most clinically distinctive feature of this variant is a gene-environment interaction²² gene-environment interaction
A pattern where a genetic variant's effect on disease depends on an environmental exposure; here, physical activity level acts as the environmental modifier. In adults who are physically active, the T allele appears to have a modest or even protective metabolic effect. In adults with sedentary behavior, T-carrier status substantially amplifies the risk of metabolic dysfunction-associated steatotic liver disease (MASLD).

The Evidence

Pediatric NAFLD (protective signal): A study by Valenti et al. 2012³³ Valenti et al. 2012
Valenti L et al. LPIN1 rs13412852 polymorphism in pediatric nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr. 2012 examined 142 children with biopsy-proven NAFLD and 337 healthy controls. The TT genotype was under-represented among pediatric NAFLD cases (7% vs 14% in controls; OR 0.58, 95% CI 0.35–0.91). Children with the TT genotype had significantly less severe liver damage (NAFLD activity score, P=0.026) and a lower prevalence of liver fibrosis (P=0.012, adjusted OR 0.29, 95% CI 0.11–0.66). The same group found TT homozygosity associated with lower triglycerides in both patients and healthy controls.

These findings fed into a 4-polymorphism pediatric NASH risk score⁴⁴ 4-polymorphism pediatric NASH risk score
Nobili V et al. 2014 — combining PNPLA3 rs738409, SOD2 rs4880, KLF6 rs3750861, and LPIN1 rs13412852 to predict NASH in obese children; AUC 0.75 for the genetic score, 0.80 for the combined clinical-genetic model.

Adult MASLD (risk signal with sedentary behavior): A 2026 Italian cohort study by Franco et al.⁵⁵ Franco et al.
Franco I et al. The Interplay of Genetics and Lifestyle in MASLD: Focus on LPIN1 rs13412852 and Sedentary Behaviour. Int J Mol Sci. 2026 genotyped 394 adults and found that CT/TT genotype was associated with MASLD independently (OR 1.80, 95% CI 1.06–3.05, P=0.03). Sedentary behavior was also an independent risk factor (OR 1.72, P <0.05). The critical finding was their interaction: individuals with both moderate-to-severe sedentary behavior and the CT/TT genotype had an MASLD risk of OR 2.99 (95% CI 1.39–6.45, P=0.005) — roughly tripling risk compared to physically active CC individuals.

UK meta-analysis (minimal effect on fasting metabolites): A meta-analysis of 8,504 UK subjects found only a nominal association between rs13412852 T allele and lower BMI (P=0.042) and slightly lower fasting insulin, with no significant association with insulin resistance overall. The authors concluded that common LPIN1 variation has no major effect on metabolic traits in isolation.

The evidence level remains emerging: the adult-sedentary interaction is a compelling finding from a single moderate-sized cohort (n=394) requiring replication. The pediatric protection signal, though biologically plausible, also requires larger studies.

Practical Actions

The most actionable implication of rs13412852 is that T-carriers should be particularly vigilant about physical inactivity. The sedentary-genotype interaction suggests that the T allele heightens the liver's vulnerability to the metabolic consequences of reduced physical activity. This is genotype- specific advice: the roughly 3-fold risk amplification in sedentary T-carriers is meaningfully larger than the sedentary risk seen in CC individuals alone.

T-carriers with existing sedentary work or lifestyle patterns should prioritize breaking sitting time with structured movement, and should monitor hepatic fat markers (liver enzymes, hepatic ultrasound) if other risk factors for MASLD are present (obesity, insulin resistance, dyslipidemia).

Interactions

This variant does not have documented gene-gene interactions, but it is part of a validated 4-variant pediatric NASH risk score alongside PNPLA3 rs738409 (I148M), SOD2 rs4880, and KLF6 rs3750861. Individuals who carry the LPIN1 T allele alongside the PNPLA3 GG risk genotype face the highest combined pediatric NASH risk in that score. The relationship between LPIN1 lipin-1 and the PPARG/PGC-1α transcriptional axis also suggests that PPARG variants (such as the Pro12Ala polymorphism) may modulate how strongly LPIN1 expression is regulated — though this gene-gene interaction has not been directly tested for rs13412852.

CYP2D6 is the enzyme behind the metabolism of roughly 25% of all prescription drugs — from antidepressants to pain medications to cancer drugs. The *2 allele, defined by the rs16947 variant (a C-to-T change causing an Arg296Cys amino acid substitution¹¹ Arg296Cys amino acid substitution
arginine to cysteine at position 296), is one of the most common CYP2D6 variants worldwide. For decades, it was classified as having "normal function," indistinguishable from the reference *1 allele. But recent research reveals a more nuanced story: this variant subtly reduces CYP2D6 expression through altered mRNA splicing, and its true impact depends heavily on what other variants accompany it on the same chromosome.

The Mechanism

The rs16947 variant alters exon 6 splicing, reducing CYP2D6 expression by at least 2-fold . The amino acid change itself (R296C) may reduce enzyme activity slightly in recombinant expression systems, but the bigger effect comes from regulatory consequences.

This SNP defines the CYP2D6*2 allele, with minor allele frequencies ranging from 17–60% across populations .

The *2 allele (rs16947) is the most frequent CYP2D6 variant in European, African, and Latino populations, though less common in East Asians where *10 predominates .

What complicates matters is that rs16947 doesn't act alone.

It's in high linkage disequilibrium with an enhancer SNP (rs5758550) located over 100 kb downstream .

The enhancer SNP increases CYP2D6 expression 2-fold, while rs16947 reduces it by 0.5-fold; haplotypes containing both variants show near-normal activity . This means that a person with two copies of the A allele at rs16947 could have anywhere from reduced to increased enzyme activity depending on the larger haplotype context — something standard genotyping panels often miss.

The Evidence

The landmark discovery came from a 2014 study²² The landmark discovery came from a 2014 study
Wang et al. Common CYP2D6 polymorphisms affecting alternative splicing and transcription. Human Molecular Genetics, 2014 that used allelic expression analysis in human liver samples.

In a pediatric cohort of 164 individuals, rs16947 alone was associated with reduced CYP2D6 metabolic activity measured by dextromethorphan ratios .

Overall allele frequencies harboring rs16947 and/or the enhancer SNP range from 17% in East Asians to 67% in Africans .

A 2019 follow-up study³³ A 2019 follow-up study
Ray et al. CYP2D6 haplotypes with enhancer SNP rs5758550 and rs16947. Pharmacogenetics and Genomics, 2019 tested the haplotype-phenotype relationship in 122 human liver microsomes.

Haplotypes containing both rs5758550 and rs16947 convey normal or slightly increased enzyme activity , supporting the idea that CYP2D6 enzyme function depends on the full haplotype, not single variants in isolation.

Despite this mechanistic evidence,

CPIC currently classifies CYP2D6*2 as having normal function , assigning it an activity score of 1.0 — the same as the reference *1 allele. This classification drives dosing guidelines for dozens of drugs, but may oversimplify for individuals whose *2 allele lacks the compensatory enhancer variant.

Practical Implications

If your 23andMe report shows the A allele at rs16947, you carry at least one copy of CYP2D6*2.

Between 43–67% of individuals have two normal-function alleles (*1 or *2) or one normal plus one decreased-function allele, resulting in normal metabolizer status . However, there is large variability in drug response within individuals genotyped as normal metabolizers, and the causes of this variation are unknown

— the *2/*enhancer haplotype interaction is a leading candidate explanation.

CYP2D6 is responsible for metabolizing many commonly prescribed drugs including antidepressants, antipsychotics, analgesics, and beta-blockers .

Pharmacogenomic clinical guidelines for at least 48 CYP2D6-substrate drugs have been developed by CPIC and other consortia. For CYP2D6*2 specifically, current guidelines treat it as normal-function and don't recommend dose adjustments. But if you experience unexpected side effects or lack of efficacy with a CYP2D6-substrate drug, the nuanced function of your *2 allele — especially if not accompanied by the enhancer — could be relevant.

The challenge is that consumer genetic tests like 23andMe typically only report rs16947 itself, not the distant enhancer SNP or the full haplotype structure. Without phased haplotype information, knowing you have *2 tells you less than it should. Clinical pharmacogenetic testing that includes copy number analysis and structural variant detection provides a more complete picture.

Interactions

The rs16947 variant interacts significantly with rs5758550 (enhancer SNP). Individuals who carry rs16947 (A allele) on a haplotype that also has rs5758550 (G allele) tend to have near-normal or slightly elevated CYP2D6 activity. Those with rs16947 but without the enhancer may have moderately reduced activity. This is a case where compound genotyping across a >100 kb span matters more than the single-SNP result.

Additionally, rs16947 defines several star alleles beyond *2, including *29, *17, *35, and others that carry additional functional variants. The *41 allele contains both rs16947 and the splicing-defect variant rs28371725, resulting in clearly reduced function. Because rs16947 is so common and appears in many haplotype backgrounds, interpreting it requires knowing what else is present on that chromosome.

For compound heterozygotes — individuals with one *2 allele and one reduced/no-function allele like *4, *5, or *10 — the impact depends on whether the *2 carries the enhancer. A *2 (with enhancer) plus *4 diplotype might behave like a normal metabolizer, while *2 (without enhancer) plus *4 could trend toward intermediate metabolism.

Before your body can build the long-chain omega-3s and omega-6s it needs for every cell membrane, every eicosanoid signal, and every synapse, it must pass dietary fatty acids through a molecular gateway: delta-6 desaturase¹¹ delta-6 desaturase
FADS2 (fatty acid desaturase 2) encodes delta-6 desaturase, the enzyme that inserts a double bond at the Δ6 position in both the omega-3 and omega-6 pathways. rs174572, an intronic variant in FADS2, alters how efficiently this gateway works. The T allele is associated with reduced desaturase activity and measurably lower circulating EPA — the omega-3 that drives anti-inflammatory eicosanoid production, platelet function, and cardiovascular protection.

The Mechanism

Delta-6 desaturase catalyzes the first and rate-limiting step in two parallel pathways: - Omega-6: linoleic acid (LA, 18:2n-6) → gamma-linolenic acid (GLA, 18:3n-6) - Omega-3: alpha-linolenic acid (ALA, 18:3n-3) → stearidonic acid (SDA, 18:4n-3)

Without adequate D6D activity, dietary precursors accumulate (higher LA and ALA in plasma) while downstream products (GLA, stearidonic acid, and ultimately EPA, DHA, and AA) remain low. rs174572 sits in intron 1 of FADS2, and — consistent with findings in the broader FADS locus — likely affects FADS2 promoter methylation and transcriptional activity²² FADS2 promoter methylation and transcriptional activity
Allele-specific methylation at FADS cluster intronic and promoter CpG sites has been confirmed in multiple tissues; intronic SNPs in high LD with the cluster tag this regulatory effect. T allele carriers produce less FADS2 enzyme, throttling both pathways simultaneously.

The Evidence

The most direct evidence comes from a genome-wide fatty acid study of 1,144 European adolescents in the HELENA cohort³³ genome-wide fatty acid study of 1,144 European adolescents in the HELENA cohort
Bokor et al. J Lipid Res 2010; 51:2325–2333; 13 FADS SNPs genotyped across 9 European countries. Carriers of the minor T allele at rs174572 showed significantly higher plasma LA (p=0.0009), higher ALA (p=0.0002), and higher DGLA — precursors that had not been converted downstream. Simultaneously, arachidonic acid was lower (p<1×10⁻⁶) and EPA was substantially lower (p=4.2×10⁻⁶). The D5D activity index (which reflects the overall efficiency of the cascade) fell from 3.70 in CC homozygotes to 3.06 in CT heterozygotes and 2.60 in TT homozygotes (p=6.1×10⁻³¹) — one of the strongest genotype-to-enzyme associations observed in the FADS gene cluster.

A 2024 scoping review of 40 studies⁴⁴ 2024 scoping review of 40 studies
Loukil, Mutch & Plourde, Genes Nutr 2024; DOI: 10.1186/s12263-024-00747-4 confirmed that minor allele carriers of rs174572 have lower circulating EPA, placing this SNP among the FADS variants with documented EPA-specific associations.

The cardiovascular relevance of FADS-driven PUFA imbalances is documented in a study of 876 subjects⁵⁵ study of 876 subjects
Martinelli et al. Am J Clin Nutr 2008 where a high AA-to-LA ratio (reflecting high D5D activity, the opposite of what T allele carriers have) independently predicted CRP elevation and coronary artery disease risk (OR ~2.55). For T allele carriers, the clinical concern is the mirror image: chronically low EPA results in reduced production of anti-inflammatory eicosanoids (prostaglandin E3, thromboxane A3) and inadequate cardiovascular protection from omega-3 signaling — without the genetic test, this functional deficiency is invisible.

Practical Actions

Because D6D activity is the first committed step in PUFA synthesis, T allele carriers cannot compensate by eating more flaxseed, chia, or walnuts. Those sources supply ALA, which still must pass through the impaired D6D gate before becoming stearidonic acid, EPA, or DHA. The only reliable route to adequate EPA is preformed EPA from marine or algae sources that bypass the conversion step entirely.

For TT homozygotes — the most affected genotype — supplementation with 2–4 g combined EPA+DHA daily from concentrated fish oil or algae-based sources is the most targeted approach. For CT heterozygotes, 1–2 g daily represents a reasonable starting point. The omega-3 index (erythrocyte EPA+DHA percentage) provides a direct, individualized measure of whether supplementation is achieving adequate tissue levels.

Interactions

rs174572 is located near rs174547, rs174546, rs174537, rs174575, and rs174589 in the FADS gene cluster on chromosome 11q12.2. These variants co-segregate as haplotype blocks, and carrying T alleles across multiple FADS cluster SNPs compounds the reduction in overall PUFA conversion capacity. The functional impact is therefore greater in individuals who carry risk alleles at both FADS2 (rs174572, D6D — the first step) and FADS1 (rs174537 or rs174547, D5D — the downstream step), as both desaturase steps become rate-limited simultaneously. This combination represents a proposal for a compound action (see harvesting notes).

Every neurotransmitter that regulates sleep — serotonin, melatonin, GABA, and dopamine — depends on the same molecular key: pyridoxal 5'-phosphate (PLP), the active form of vitamin B6. Dietary vitamin B6 (pyridoxine or pyridoxamine from food and most supplements) is not active on its own. Before your brain can use it, the enzyme PNPO¹¹ PNPO
Pyridoxamine 5'-phosphate oxidase — catalyzes the final oxidation step converting PNP and PMP to PLP, the biologically active cofactor form of vitamin B6 (pyridoxamine 5'-phosphate oxidase) must convert it to PLP. The rs17679445 Arg116Gln variant substitutes a glutamine for arginine at position 116 of PNPO, reducing the enzyme's catalytic efficiency and thereby limiting the supply of PLP to the neurotransmitter-synthesizing enzymes that depend on it.

The Mechanism

PNPO sits at the final step of B6 activation. It oxidizes both pyridoxine 5'-phosphate (PNP) and pyridoxamine 5'-phosphate (PMP) into PLP. Without adequate PLP, multiple downstream enzymes falter simultaneously. The most sleep-relevant are:

• Aromatic amino acid decarboxylase (AADC/DDC) — converts 5-HTP to serotonin and L-DOPA to dopamine; requires PLP as essential cofactor. A 2022 structural study²² 2022 structural study
  Al Mughram MH et al. Elucidating the Interaction between Pyridoxine 5'-Phosphate Oxidase and Dopa Decarboxylase. Int J Mol Sci, 2022 showed that PNPO physically binds to AADC and directly delivers PLP to it — making PNPO's efficiency a rate-limiting step for serotonin and dopamine production.
• Glutamic acid decarboxylase (GAD) — converts glutamate to GABA, the brain's primary inhibitory neurotransmitter; PLP-dependent. Reduced GAD activity is the central mechanism in PNPO-deficiency epilepsy.
• Tryptophan aminotransferase — a PLP-dependent enzyme in the melatonin synthesis pathway. Lower PLP availability reduces pineal melatonin output, as demonstrated in B6-deficient animal models³³ B6-deficient animal models
  Dakshinamurti K et al. Neuroendocrinology of pyridoxine deficiency. Neurosci Biobehav Rev, 1988 where B6 deficiency reduced both hypothalamic serotonin and pineal melatonin.

The Arg116Gln substitution replaces a positively charged arginine (which stabilizes the enzyme's active site) with a neutral glutamine. While this does not abolish enzyme function (unlike homozygous loss-of-function mutations that cause neonatal epilepsy), it reduces catalytic efficiency — producing a partial, dose-dependent reduction in PLP output that is particularly relevant in carriers who consume standard (non-activated) vitamin B6 supplements or have modest dietary B6 intake.

The Evidence

The variant's association with insomnia was identified in the landmark Jansen et al. 2019⁴⁴ Jansen et al. 2019
Jansen PR et al. Genome-wide analysis of insomnia in 1,331,010 individuals identifies new risk loci and functional pathways. Nature Genetics, 2019 genome-wide association study of 1,331,010 individuals, which identified 202 insomnia risk loci implicating 956 genes. The PNPO locus on chromosome 17 was among the hits. While GWAS identifies association rather than causation, the biological plausibility is high: the entire neurotransmitter cascade governing sleep initiation and maintenance — serotonin → melatonin, GABA synthesis, dopamine signaling — converges on PLP as a shared cofactor.

A comprehensive 2019 review⁵⁵ comprehensive 2019 review
Wilson MP et al. Disorders affecting vitamin B6 metabolism. J Inherit Metab Dis, 2019 of vitamin B6 metabolism disorders confirmed that PLP (produced by PNPO) is the sole active cofactor form capable of driving neurotransmitter synthesis reactions in the central nervous system.

Supporting the sleep-B6 link at a clinical level, two controlled trials showed that vitamin B6 supplementation affects sleep architecture. An RCT by Ebben et al. (2002)⁶⁶ RCT by Ebben et al. (2002)
Ebben M et al. Effects of pyridoxine on dreaming: a preliminary study. Perceptual and Motor Skills, 2002 found that 250 mg pyridoxine before sleep significantly enhanced dream salience (vividness, emotionality, color) compared to placebo over 5 nights, hypothesizing enhanced B6-to-serotonin conversion as the mechanism. A larger RCT by Aspy et al. (2018)⁷⁷ RCT by Aspy et al. (2018)
Aspy DJ et al. Effects of Vitamin B6 (Pyridoxine) and a B Complex Preparation on Dreaming and Sleep. Perceptual and Motor Skills, 2018 replicated increased dream recall in 100 participants taking 240 mg pyridoxine.

ClinVar classifies the A allele (Arg116Gln) as benign for PNPO-deficiency epilepsy — consistent with the protein retaining substantial function. The sleep association reflects a subtler, quantitative reduction in PLP production relevant at the population level rather than a clinical disease state.

Practical Actions

The key insight for Arg116Gln carriers is the bypass strategy: while standard vitamin B6 supplements contain pyridoxine or pyridoxamine that require PNPO to activate, pyridoxal-5-phosphate (P5P) is the already-activated form that enters cells and reaches neurotransmitter- synthesizing enzymes without needing PNPO conversion. Using P5P directly circumvents the enzymatic bottleneck at the Arg116Gln substitution.

Homozygous A carriers (Arg116Gln/Arg116Gln) represent the extreme of impaired conversion and should particularly consider P5P supplementation. Heterozygous AG carriers have an intermediate phenotype with partial reduction in conversion efficiency.

Interactions

PNPO Arg116Gln is most likely to be clinically relevant in the context of other factors that further stress PLP availability: low dietary B6 intake, high protein intake (which increases B6 demand for amino acid metabolism), oral contraceptive use (which depletes B6), or genetic variants in B6 transport or metabolism. No specific gene-gene interaction studies with rs17679445 have been published, but carriers of both PNPO Arg116Gln and variants affecting tryptophan metabolism (e.g., MTHFR, which shares PLP-dependent enzymes in the one-carbon cycle) may experience compounded effects on neurotransmitter synthesis.

PPARα¹¹ PPARα
Peroxisome Proliferator-Activated Receptor Alpha — a nuclear receptor transcription factor that acts as the master regulator of fatty acid oxidation, lipoprotein metabolism, and energy substrate utilization during fasting and exercise is one of the most important lipid-sensing proteins in the human body. It responds to dietary fats, exercise, and fasting by switching on a gene expression program that burns fat for energy and clears lipids from the bloodstream. The Leu162Val missense variant (rs1800206) substitutes valine for leucine at position 162 of the PPARα protein, subtly altering the receptor's transcriptional behavior — with consequences that depend strongly on what you eat.

The Mechanism

Position 162 sits in the DNA-binding domain²² DNA-binding domain
The DNA-binding domain of PPARα recognizes specific peroxisome proliferator response elements (PPREs) in gene promoters and, once ligand-activated, drives transcription of target genes involved in fatty acid oxidation, lipoprotein lipase production, and apolipoprotein synthesis of the PPARα protein. In vitro experiments show that the Val162 variant (G allele) produces consistently lower transcriptional activation³³ consistently lower transcriptional activation
Rudkowska et al. 2009 (PPAR Res) showed V162 cells had significantly lower PPARα and APOA1 expression after EPA and DHA treatment in HepG2 hepatoma cells than L162 wild-type cells than the common Leu162 form when stimulated with omega-3 fatty acids. This blunted responsiveness translates into downstream effects: lower lipoprotein lipase (LPL) activity, reduced clearance of triglyceride-rich lipoproteins, and less efficient production of ApoA-I (a key structural protein in HDL particles).

The paradox of this variant is that despite reduced intrinsic activity, V162 carriers do not uniformly show worse lipid profiles — the consequences depend critically on dietary fat composition. When dietary polyunsaturated fatty acid (PUFA) intake is low, the variant exposes its metabolic vulnerability; when PUFA intake is adequate (≥8% of energy), the phenotype largely normalizes.

The Evidence

The largest genetic epidemiology evidence comes from the Framingham Offspring Study⁴⁴ Framingham Offspring Study
Tai ES et al. Association between the PPARA L162V polymorphism and plasma lipid levels: the Framingham Offspring Study. Arterioscler Thromb Vasc Biol, 2002, which genotyped 2,373 participants (V162 allele frequency 6.9%) and found significant associations in men: higher LDL cholesterol (P=0.0004), higher total cholesterol (P=0.0012), higher ApoB (P=0.009), and elevated ApoC-III concentrations — all pointing toward impaired clearance of atherogenic lipoproteins.

The gene-diet interaction was characterized elegantly in the Framingham Heart Study dietary analysis⁵⁵ Framingham Heart Study dietary analysis
Tai ES et al. Polyunsaturated fatty acids interact with the PPARA-L162V polymorphism to affect plasma triglyceride and apolipoprotein C-III concentrations in the Framingham Heart Study. J Nutr, 2005, where V162 carriers on low PUFA diets (<6% of energy) showed approximately 28% higher plasma triglycerides than L162 homozygotes (P<0.01), while V162 carriers on high-PUFA diets (>8% of energy) showed 4% lower triglycerides. The interaction was dose-dependent and highly significant (P=0.031 for triglycerides, P<0.001 for ApoC-III), confirming that dietary fat composition determines whether this variant is harmful or neutral.

In a cohort of 610 young adults, Robitaille et al.⁶⁶ Robitaille et al.
Robitaille J et al. PPARalpha L162V underlies variation in serum triglycerides and subcutaneous fat volume in young males. BMC Med Genet, 2007 found that V allele males had 78% higher serum triglycerides than LL homozygotes (208 vs 116 mg/dL, P=0.004) and significantly lower HDL cholesterol (34 vs 42 mg/dL, P=0.001). The variant also predicted an unusual response to exercise training: V allele males actually increased subcutaneous fat in the untrained limb during unilateral resistance training, while LL males reduced fat. Women showed no effect — suggesting the variant's lipid impact is sex-specific.

At the molecular level, two complementary studies by Rudkowska and colleagues⁷⁷ two complementary studies by Rudkowska and colleagues
Rudkowska I et al. Omega-3 fatty acids regulate gene expression levels differently in subjects carrying the PPARalpha L162V polymorphism. Genes Nutr, 2009 confirmed that V162 carriers show significantly blunted PPARα and ApoA-I gene expression in response to DHA supplementation — meaning the mechanism for HDL generation is impaired. A paired in vivo/in vitro study (PMID 19937854)⁸⁸ (PMID 19937854) further showed that n-3 fatty acid-induced LPL activity increase was roughly halved in V162 carriers (6.6% vs 14.4%), reducing their capacity to clear triglycerides from the blood.

In the STOP-NIDDM trial⁹⁹ STOP-NIDDM trial
Andrulionyte L et al. PPARA gene polymorphisms influence conversion from impaired glucose tolerance to type 2 diabetes: the STOP-NIDDM trial. Diabetes, 2007, the G (Val162) allele increased the risk of progressing from impaired glucose tolerance to overt type 2 diabetes by 1.9-fold (95% CI 1.05–3.58) in the placebo group among 767 participants, with associated elevations in plasma glucose and insulin — likely reflecting the impaired fatty acid oxidation and lipotoxicity consequences of reduced PPARα activity.

There is also an exercise context: a 12-week aerobic training intervention in 168 women (PMID 31319591)¹⁰¹⁰ (PMID 31319591) found that CG genotype carriers showed a decrease in HDL cholesterol after the program, in contrast to the expected improvements in CC carriers — consistent with the reduced PPARα-driven APOA1 response documented in molecular studies.

Practical Actions

The core insight for V162 allele carriers is that dietary PUFA intake is the primary modifiable lever. The gene-diet interaction is one of the cleaner pharmacogenomic effects in nutritional genomics: omega-3 fatty acids act as direct PPARα ligands and should theoretically be most helpful, yet the V162 variant blunts exactly this response. At the same time, the evidence from the fibrate pharmacogenomics literature shows paradoxical benefit — V162 carriers showed dramatically better HDL response to gemfibrozil (a fibrate that directly activates PPARα), suggesting that at sufficiently high levels of PPARα stimulation, the reduced-activity receptor can still be mobilized.

The practical implication: V162 carriers should monitor lipids proactively, maintain high-quality PUFA intake (even if the response is attenuated, low PUFA unmistakably worsens the phenotype), and be aware that standard aerobic exercise programs may not improve HDL as expected. If pharmacotherapy for lipids becomes necessary, fibrate drugs may show above-average HDL benefit in V162 carriers.

Interactions

This variant is in the same gene as rs4253778 (PPARA intron 7 G/C). The intron 7 variant alters PPARA expression level and muscle fiber composition; Leu162Val alters PPARA protein function. They address distinct molecular mechanisms and are not in high LD with each other, allowing independent contributions. Combined unfavorable alleles (CC at rs4253778 and CG/GG at rs1800206) may compound adverse lipid responses to exercise training — the existing rs4253778 entry already notes this interaction (C allele at rs4253778 combined with Val162 at rs1800206 has been associated with more pronounced adverse lipid changes during training).

PPARD (rs2016520, rs1053049) works in the same fat-oxidation pathway as PPARA. While both nuclear receptors regulate lipid metabolism, their actions are largely independent at the genotype level; no formal interaction studies between rs1800206 and PPARD variants have been published in exercise cohorts. The PPARGC1A Gly482Ser variant (rs8192678) is a PGC-1alpha coactivator that physically interacts with PPARα; combined analysis with rs1800206 has not been studied but represents a plausible compound effect.

Every day your liver makes a protein called CETP¹¹ CETP
Cholesteryl Ester Transfer Protein — an enzyme that shuttles cholesteryl esters from protective HDL particles to LDL and VLDL, effectively draining your HDL of its cargo. The more CETP your liver produces, the lower your HDL cholesterol tends to be. A single nucleotide change in the CETP gene's promoter region — 629 bases upstream of the transcription start site — determines how much CETP your liver produces, and therefore shapes your HDL cholesterol set point from birth.

The Mechanism

The -629 position sits within a Sp1/Sp3 transcription factor binding site²² Sp1/Sp3 transcription factor binding site
Sp1 and Sp3 are zinc-finger proteins that bind GC-rich DNA sequences and regulate transcription — Sp3 commonly acts as a repressor when it outcompetes Sp1 at the same site. The C allele creates a sequence that Sp1 and Sp3 bind poorly. The A allele creates a high-affinity Sp1/Sp3 binding site — and Sp3 at this position acts as a transcriptional repressor, suppressing CETP gene expression by approximately 25%.

Carriers of the A allele therefore have lower circulating CETP protein. Because CETP transfers cholesteryl esters from HDL to LDL and VLDL, less CETP activity means cholesteryl esters accumulate inside HDL particles — raising measured HDL cholesterol. The original mechanistic study by Dachet et al.³³ original mechanistic study by Dachet et al. showed that CC homozygotes had 0.45 μg/mL higher circulating CETP mass than AA homozygotes, and correspondingly lower HDL-C levels, in 536 subjects from the ECTIM study.

The Evidence

The largest and most rigorous study of this variant is the Women's Genome Health Study (WGHS)⁴⁴ Women's Genome Health Study (WGHS)
Ridker et al. 2009; 18,245 initially healthy American women of European ancestry, followed prospectively for ~10 years for cardiovascular events. In this genome-wide analysis, rs1800775 was identified as the single most strongly associated SNP in the entire CETP region for HDL-C. HDL-C was approximately 52 mg/dL in CC carriers, 52 mg/dL in CA carriers, and 54 mg/dL in AA homozygotes. The age-adjusted hazard ratio for myocardial infarction was 0.82 per A allele (P=0.048), though this association was attenuated when HDL-C was included in the model (HR 0.90, P=0.31) — suggesting the cardiovascular effect operates largely through HDL.

A 2015 resequencing study⁵⁵ 2015 resequencing study
Pirim et al. Metabolism 2015; 602 non-Hispanic whites and 353 African blacks confirmed that rs1800775 independently associates with HDL-C in both European and African populations. Importantly, in Europeans this variant is in strong LD with TaqIB (rs708272, r²=0.75), but in African Americans LD is much weaker (r²=0.19) — meaning rs1800775 and TaqIB may capture largely overlapping signals in Europeans but distinct functional variation in Africans.

A meta-analytic evaluation⁶⁶ meta-analytic evaluation of 17 studies (5,441 CHD cases, 7,967 controls, 22,488 subjects in lipid analyses) found that the C allele associates with 3.65–4.36 mg/dL lower HDL-C and 0.45 μg/mL higher CETP mass. Among Caucasian populations, CC carriers had significantly higher CHD odds (OR 1.41–1.43 under dominant/homozygous models), while overall association in mixed populations was not significant — consistent with population heterogeneity in LD structure.

The HDL-C Paradox

A critical nuance: CETP variants that raise HDL by reducing cholesteryl ester transfer do not always translate into the same cardiovascular protection as HDL raised by other means. The HDL-raising effect of the -629A allele is partly attenuated by elevated triglycerides⁷⁷ partly attenuated by elevated triglycerides
When TG-rich lipoproteins are high, CETP transfer activity from HDL becomes dominated by mass-action effects of the TG substrate; CETP genotype effects on HDL diminish in high-TG states. The interaction between CETP genotype and plasma triglycerides means that the -629A benefit on HDL is largest at low triglyceride levels.

Practical Actions

For CC homozygotes, CETP expression is at its highest reference level, and HDL-C tends to run 3–6 mg/dL lower than in AA homozygotes. This is a modest but consistent effect operating as a background risk factor for low HDL. Lifestyle-level intervention can offset the genotype: aerobic exercise is one of the most robust HDL-raising stimuli and works regardless of CETP genotype. Dietary fat quality (replacing saturated fat with unsaturated fat) also supports HDL levels. The clinical priority for CC individuals is ensuring HDL-C is monitored regularly and that other lipid risk factors (LDL, triglycerides) are well managed, since the genotype alone does not cause disease.

For CA heterozygotes, HDL-C is in the population range but slightly elevated relative to CC individuals. No specific intervention is required.

For AA homozygotes, lower CETP activity raises HDL-C. Monitoring the full lipid panel rather than HDL alone is worthwhile: if HDL is elevated alongside high triglycerides, the cardiovascular benefit is reduced.

Interactions

rs1800775 is in strong LD with the CETP TaqIB variant rs708272 in European populations (r²=0.75). Tests that report TaqIB are largely capturing the same signal in Europeans, though rs1800775 is considered the functional variant given its direct transcriptional effect. In African ancestry populations, the two SNPs are only weakly correlated (r²=0.19), and both should be assessed independently.

CETP variants interact additively with LIPC variants (rs1532085) in raising HDL-C, but studies suggest the CETP-side interaction is what primarily translates to cardiovascular benefit. For individuals carrying CETP CC and LIPC GG genotypes, HDL may be at its lowest for both loci and monitoring is most important.

Interleukin-10 (IL-10) is the body's master anti-inflammatory cytokine¹¹ the body's master anti-inflammatory cytokine
IL-10 suppresses production of pro-inflammatory cytokines like TNF-α, IL-6, and IL-1β, acting as a critical brake on immune responses to prevent excessive inflammation. The IL10 gene on chromosome 1²² chromosome 1
Located at 1q31-32, position 206,773,062 encodes this regulatory cytokine. The -592 C>A polymorphism (rs1800872) sits in the promoter region, functioning as a dimmer switch that determines how much IL-10 your cells produce when inflammation begins. Unlike rs1800896 (IL10 -1082), which is already documented in GeneOps' immune-gut category, rs1800872 provides additional resolution on the IL-10 haplotype and captures distinct cardiovascular and metabolic inflammation angles.

The Mechanism

The -592 position is part of a highly polymorphic promoter region³³ highly polymorphic promoter region
The three main IL10 promoter SNPs (-1082, -819, -592) exhibit strong linkage disequilibrium and form distinct haplotypes that forms three predominant haplotypes controlling IL-10 transcription: GCC (high producer), ACC (intermediate), and ATA (low producer). The A allele at -592 is a component of the ATA haplotype⁴⁴ ATA haplotype
Associated with 2-4 fold reduction in IL-10 transcription, which causes considerably reduced promoter function and decreased IL-10 gene expression. The C-to-A exchange at position -592 disrupts transcription factor binding⁵⁵ disrupts transcription factor binding
Affects binding sites that regulate how actively the gene is transcribed into mRNA, leading to lower IL-10 production in response to inflammatory stimuli.

The functional impact creates a paradoxical situation: higher IL-10 production generally suppresses inflammation⁶⁶ higher IL-10 production generally suppresses inflammation
IL-10 downregulates synthesis of IL-1, IL-6, and TNF-α, which should be protective. However, in cardiovascular contexts, the AA genotype (low IL-10 producer) shows mixed associations—in some studies linked with increased atherosclerosis and coronary artery disease risk⁷⁷ increased atherosclerosis and coronary artery disease risk
Chinese population study found A allele associated with CAD, OR varies by population, yet paradoxically also associated with elevated HDL cholesterol, reduced intima-media thickness, and less peripheral artery stenosis⁸⁸ elevated HDL cholesterol, reduced intima-media thickness, and less peripheral artery stenosis
Russian study of acute coronary syndrome patients in certain populations. This complexity reflects IL-10's dual role: too little allows unchecked inflammation, but chronic elevation can signal uncontrolled inflammatory disease.

The Evidence

Cancer protection⁹⁹ Cancer protection
Meta-analysis of 70 studies encompassing 16,785 cases and 19,713 controls provides the strongest evidence: the AA genotype confers moderately decreased cancer risk (OR 0.90, 95% CI 0.83-0.98) compared to CC. The protective effect is particularly strong in smoking-related cancers (OR 0.77) and Asian populations (OR 0.79)¹⁰¹⁰ smoking-related cancers (OR 0.77) and Asian populations (OR 0.79). The mechanism likely involves the balance between anti-tumor immunity (requires some inflammation to clear cancer cells) versus chronic inflammation (which promotes tumorigenesis). Lower IL-10 production in AA carriers may allow more effective immune surveillance of pre-malignant cells.

Cardiovascular associations are more nuanced. A Chinese case-control study¹¹¹¹ Chinese case-control study
326 CAD patients vs. 248 controls found the A allele associated with increased coronary artery disease risk, with AA genotype carriers showing higher risk of >50% stenosis. Yet a Russian study¹²¹² Russian study
220 acute coronary syndrome patients found AA genotype carriers had elevated HDL cholesterol, reduced carotid intima-media thickness, lower frequency of peripheral artery stenosis, and—critically—increased IL-10 production despite the functional data suggesting the opposite. This paradox may reflect compensatory upregulation in the setting of active disease or population-specific genetic backgrounds.

The type 2 diabetes association is clearer. A North Indian study¹³¹³ North Indian study
260 T2DM patients vs. 280 controls found diabetes patients carried significantly more A alleles at -592 (25.6% vs. controls, P < 0.001). The mechanism involves chronic low-grade inflammation¹⁴¹⁴ mechanism involves chronic low-grade inflammation
Low serum IL-10 associated with increased T2DM and metabolic syndrome susceptibility—insufficient IL-10 allows persistent activation of inflammatory pathways that drive insulin resistance. Genotype-specific analysis showed CC genotype associated with T2DM¹⁵¹⁵ CC genotype associated with T2DM
Contrasting with AA's association with elevated HDL, while AA genotype paradoxically linked to both increased HDL and increased IL-10 in some cohorts.

In systemic lupus erythematosus¹⁶¹⁶ systemic lupus erythematosus
Iranian population study of 70 SLE patients vs. 211 controls, IL10 promoter polymorphisms including rs1800872 showed haplotype-dependent associations with disease activity and IL-10 levels. The complexity reflects IL-10's context-dependent effects: protective against inflammatory damage, yet high levels may indicate failure to resolve inflammation.

COVID-19 severity studies¹⁷¹⁷ COVID-19 severity studies
Brazilian and Egyptian cohort studies demonstrated that IL10 haplotypes (including -592) influence infection severity, with GCC haplotype homozygosity (high IL-10 producer) independently associated with severe disease (OR 2.77), possibly through excessive immunosuppression preventing viral clearance.

Practical Implications

Your genotype at -592 influences your baseline inflammatory regulation and may modulate risk for conditions ranging from cardiovascular disease to cancer to metabolic syndrome. The evidence suggests that IL-10 production exists in a Goldilocks zone—too little permits unchecked inflammation (atherosclerosis, insulin resistance), while chronic elevation signals inflammatory disease burden.

For cardiovascular health, the A allele shows population-specific and context-dependent effects. In some Asian populations it associates with increased CAD risk; in Eastern European populations with protective lipid profiles. The key insight: IL-10 is a marker of inflammatory tone, not a standalone risk factor. If you carry AA or AC genotypes, focus on anti-inflammatory dietary patterns¹⁸¹⁸ anti-inflammatory dietary patterns
Mediterranean diet consistently shows reductions in inflammatory markers including increased IL-10 rather than trying to "boost IL-10" in isolation.

For cancer risk, AA carriers show modest protection, particularly for smoking-related cancers. This isn't actionable in the sense of changing your genotype, but it underscores the importance of avoiding tobacco—the protective effect is stronger in smoking-exposed populations, suggesting lower IL-10 production may help clear pre-malignant cells in high-exposure settings.

For metabolic health, lower IL-10 production (AA genotype) may increase vulnerability to insulin resistance through chronic inflammatory signaling. Interventions that boost IL-10¹⁹¹⁹ Interventions that boost IL-10
Curcumin, omega-3s, Mediterranean diet, and mind-body practices increase IL-10 include omega-3 fatty acids (EPA/DHA), curcumin supplementation, vitamin D optimization, and mind-body practices like meditation that have been shown to increase IL-10 while reducing pro-inflammatory cytokines²⁰²⁰ increase IL-10 while reducing pro-inflammatory cytokines
Mindfulness retreat study showed significant IL-10 increases and IL-6/IL-8 reductions.

Interactions

The -592 variant (rs1800872) works in concert with two other IL10 promoter SNPs: -1082 A>G (rs1800896)²¹²¹ -1082 A>G (rs1800896)
Already documented in GeneOps' immune-gut category and -819 C>T (rs1800871). These three variants exhibit strong linkage disequilibrium²²²² strong linkage disequilibrium
They travel together on chromosomes forming specific haplotype blocks and form haplotypes that determine IL-10 production capacity:

• GCC haplotype (high IL-10 producer): -1082G / -819C / -592C — associated with elevated IL-10 secretion, which generally suppresses inflammation but in COVID-19 studies linked to severe disease²³²³ linked to severe disease
  GCC homozygosity OR 2.77 for severe COVID, possibly through excessive immunosuppression

• ATA haplotype (low IL-10 producer): -1082A / -819T / -592A — associated with 2-4 fold reduced IL-10 transcription, linked to increased inflammatory disease susceptibility²⁴²⁴ linked to increased inflammatory disease susceptibility
  Low IL-10 producer haplotype in multiple autoimmune and inflammatory conditions but potential cancer protection

• ACC haplotype (intermediate): -1082A / -819C / -592C — intermediate IL-10 production

Understanding your full IL-10 haplotype requires knowing all three positions. If you're AA at -592, you likely carry at least one copy of the low-producer ATA haplotype, particularly if you also carry AA at -1082 (rs1800896). The combined effect is stronger than either variant alone—haplotype analysis in Iranian SLE patients²⁵²⁵ Iranian SLE patients
Study of 70 patients vs. 211 controls showed haplotype associations with disease activity that weren't apparent from single-SNP analysis.

The interaction with environmental factors is critical. Mindfulness and stress reduction interventions²⁶²⁶ Mindfulness and stress reduction interventions
Meta-analysis of mind-body interventions across multiple inflammatory diseases significantly increase IL-10 production, potentially compensating for genetically low expression. Similarly, omega-3 supplementation²⁷²⁷ omega-3 supplementation
EPA specifically lowers TNF-α/IL-10 ratio and dietary patterns like the Mediterranean diet combined with curcumin²⁸²⁸ Mediterranean diet combined with curcumin
RCT in ulcerative colitis patients show synergistic effects on inflammatory markers including IL-10.

Deep inside every cell, mitochondria must replicate their own small genome — a 16,569 base pair circle of DNA encoding 13 essential proteins of the electron transport chain. This task falls to TFAM (Transcription Factor A, Mitochondrial), a compact protein that wraps around mitochondrial DNA, initiates its transcription, and oversees its replication and repair. Without adequate TFAM activity, mitochondria lose the capacity to maintain their genome, energy production falters, and the accelerated mitochondrial DNA deletions and mutations that characterize aging accumulate faster.

The rs1937 variant (+35G>C in exon 1) sits in a particularly sensitive position: codon 12 of TFAM, within the mitochondrial targeting sequence that guides the nascent protein into the mitochondrion. The common G allele encodes serine at position 12 (S12), while the rarer C allele encodes threonine (T12). This conservative amino acid swap — both serine and threonine are small polar residues — nonetheless affects TFAM function in ways that appear to matter across the lifespan.

The Mechanism

The Ser12Thr substitution sits in the N-terminal mitochondrial targeting sequence (MTS), the signal peptide that is cleaved after import into the mitochondrion. Although this signal peptide does not become part of the mature TFAM protein, its amino acid composition influences the efficiency and fidelity of mitochondrial import. The Thr12 (C allele) variant may alter the hydrophobicity or secondary structure of the MTS in ways that affect import kinetics, or may influence co-translational regulation of the full-length precursor.

TFAM is a direct transcriptional target of NRF1, placing it downstream in the canonical mitochondrial biogenesis cascade: exercise and nutrient stress activate PGC-1α → PGC-1α co-activates NRF1 → NRF1 drives TFAM expression → TFAM enters mitochondria to replicate mtDNA and drive transcription of electron transport chain subunits. Variation at rs1937 therefore sits at the endpoint of a pathway already shaped by NRF1 variants rs6949152 and rs2402970, both of which are in the GeneOps database.

Mitochondrial function decline is one of the nine hallmarks of aging. TFAM abundance is reduced in aged tissues and in Alzheimer's disease brains; restoring TFAM in animal models has extended lifespan and reduced neurodegeneration. The rs1937 C allele appears to preserve mitochondrial function in aging in ways the common G allele does not fully replicate.

The Evidence

The clearest longevity signal comes from two independent case-control cohorts on different continents. In a Spanish centenarian cohort¹¹ In a Spanish centenarian cohort
Santiago et al. Mitochondriogenesis genes and extreme longevity. Rejuvenation Res. 2013 examining 107 centenarians against 284 young adults, the CC genotype appeared exclusively in the centenarian group — 2.8% of centenarians carried it, while it was absent in controls entirely (p=0.003). The effect was striking given the study's modest size.

The more powered replication comes from China. The CLHLS cohort study²² The CLHLS cohort study
Zhu et al. Association between SNP of rs1937 in TFAM and longevity among the elderly Chinese. BMC Geriatrics. 2022 compared 1,907 long-lived individuals (≥90 years) against 1,387 young elderly (65–74 years) and found the CC genotype associated with longevity (OR 1.989, 95% CI 1.160–3.411, p=0.003). The C-allele frequency was 16.9% in long-lived participants vs 14.2% in younger controls, a modest but statistically significant enrichment. The association strengthened among those not living alone, suggesting social engagement may amplify or moderate the genetic effect.

Evidence for the G allele as a risk factor spans Alzheimer's disease research as well. A Spanish AD cohort³³ A Spanish AD cohort
Gómez-Durán et al. TFAM gene variation and risk of late-onset Alzheimer's disease. J Alzheimers Dis. 2008 found GG homozygosity significantly more frequent in 300 LOAD patients than in 183 healthy controls (92% vs 86%, OR 1.91, p=0.04). A German study⁴⁴ A German study
Günther et al. Possible association of TFAM genotype with sporadic Alzheimer disease. Neurosci Lett. 2004 of 372 AD patients and 295 controls identified a TFAM haplotype carrying the rs1937 G allele as a moderate risk factor, particularly in women. And a Norwegian cognitive study⁵⁵ a Norwegian cognitive study
Bøttger et al. TFAM rs1937 and APE1 rs1130409 alleles associated with reduced cognitive performance. Neurosci Lett. 2017 found G-allele carriers showed reduced MMSE scores across AD patients, patient controls, and healthy controls.

It should be noted that one Han Chinese study found the C allele protective against AD in that population — the evidence is consistent in direction (C protective, G risk) but the effect magnitudes and statistical confidence vary across cohorts, reflecting genuine biological heterogeneity and modest sample sizes.

The overall picture points to rs1937 as an emerging longevity-relevant variant with preliminary-to-moderate evidence: the C allele is enriched in long-lived individuals, and the G allele associates with cognitive decline and Alzheimer's risk. The evidence is not yet at the level of established longevity markers like FOXO3 rs2802292 or APOE, but the NRF1→TFAM biological axis is compelling and the two independent longevity associations strengthen the signal.

Practical Implications

For individuals carrying the GG genotype, lifestyle choices that maximize TFAM expression and mitochondrial function become especially important. Endurance and resistance exercise are the most potent natural inducers of the PGC-1α→NRF1→TFAM pathway — both have documented capacity to upregulate TFAM protein and mtDNA copy number in muscle and brain tissue. Caloric restriction and intermittent fasting activate the same cascade through AMPK and SIRT1 signaling.

Mitochondria-targeted antioxidant strategies may also be relevant. Coenzyme Q10 and MitoQ (mitochondria-targeted ubiquinone) support electron transport chain efficiency and reduce mitochondrial ROS production — the primary driver of mtDNA damage that TFAM must continuously repair. Reducing chronic inflammation through diet and lifestyle reduces the oxidative burden on mitochondrial DNA.

Cognitive monitoring deserves attention for GG carriers given the Alzheimer's association data, particularly those with a family history of neurodegenerative disease. Aerobic exercise has the strongest evidence base for maintaining mitochondrial function in the brain and reducing AD risk independent of genetics.

Interactions

rs1937 sits at the bottom of the NRF1→TFAM axis. Individuals carrying risk variants in both upstream regulators — NRF1 rs6949152 (G allele) and NRF1 rs2402970 — and the downstream rs1937 G allele may have compounded reductions in mitochondrial biogenesis capacity. The upstream regulator PPARGC1A rs8192678 (the PGC-1α Gly482Ser variant) further shapes this pathway; carriers of the Ser allele show reduced PGC-1α activity, which would amplify any downstream TFAM insufficiency.

The broader longevity context places rs1937 alongside FOXO3 rs2802292: both are downstream effectors of cellular stress-resistance pathways, both show their most consistent effects in oxidative-stress and energy-metabolism biology, and both point toward exercise and hormetic interventions as the actionable mitigation strategy.